Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00361-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Thomas Katairo und 29 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Collaboration, Kampala, Uganda. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Malaria, Falciparum, Drug Resistance. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Bill and Melinda Gates Foundation, Bill & Melinda Gates Foundation.
Abstract (Originalsprache)
The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Research Collaboration, Kampala, Uganda.
- National Malaria Reference and Research Laboratory (NMRRL), Central Public Health Laboratories (CPHL), Kampala, Uganda.
- Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
- Makerere University, Kampala, Uganda.
- African Center of Excellence in Bioinformatics and Data Intensive Sciences, Kampala, Uganda.
- University of California, San Francisco, USA.
ORCID-Profile: Thomas Katairo, Victor Asua, Francis D Semakuba, Bienvenu Nsengimaana, Shahiid Kiyaga, Nicholas Hathaway, Kathryn Murie, Stephen Tukwasibwe, Innocent Wiringilimaana, Caroline Mwubaha, Trevor E Esilu, Alisen Ayitewalah, Monica Mbabazi, Kisakye D Kabbale, Jerry Mulondo, Andrés Aranda-Diaz, Catherine S Maiteki, Jimmy Opigo, Grant Dorsey, Samuel L Nsobya, Moses R Kamya, Bosco B Agaba, Isaac Ssewanyana, Bryan Greenhouse, Philip J Rosenthal, Jessica Briggs
Förderung
- NIAID NIH HHS
- Bill and Melinda Gates Foundation
- Bill & Melinda Gates Foundation
- NIH HHS
- Gates Foundation
- National Institutes of Health
Zitieren
APA
Katairo, T., Asua, V., Semakuba, F. D., Nsengimaana, B., Kiyaga, S., Hathaway, N., Murie, K., Tukwasibwe, S., Wiringilimaana, I., Nakasaanyaa, J., Mwubaha, C., Achom, K. B., Esilu, T. E., Ayitewalah, A., Mbabazi, M., Kabbale, K. D., Mulondo, J., Watyekele, E., Aranda-Diaz, A., …, & Conrad, M. D. (2026). Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00361-26
Vancouver
Katairo T, Asua V, Semakuba FD, Nsengimaana B, Kiyaga S, Hathaway N, et al. Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00361-26
BibTeX
@article{Katairo2026,
author = {Katairo, Thomas and Asua, Victor and Semakuba, Francis D and Nsengimaana, Bienvenu and Kiyaga, Shahiid and Hathaway, Nicholas and Murie, Kathryn and Tukwasibwe, Stephen and Wiringilimaana, Innocent and Nakasaanyaa, Jackie and Mwubaha, Caroline and Achom, Karen B and Esilu, Trevor E and Ayitewalah, Alisen and Mbabazi, Monica and Kabbale, Kisakye D and Mulondo, Jerry and Watyekele, Eric and Aranda-Diaz, Andrés and Maiteki, Catherine S and Opigo, Jimmy and Dorsey, Grant and Nsobya, Samuel L and Kamya, Moses R and Agaba, Bosco B and Ssewanyana, Isaac and Greenhouse, Bryan and Rosenthal, Philip J and Briggs, Jessica and Conrad, Melissa D},
title = {Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00361-26}
}
EUVIMED